Summary
Regeneron Pharmaceuticals, Inc. (REGN) filed an 8-K on May 8, 2014, to report its financial and operating results for the first quarter ended March 31, 2014. The filing incorporates by reference a press release issued on the same date, which contains the detailed results. Investors should review this press release for key performance indicators, revenue figures, and commentary on the company's progress and outlook for the period.
Key Highlights
- 1Filing reports Q1 2014 financial and operating results.
- 2Key financial and operational details are available in the press release (Exhibit 99.1).
- 3The press release provides an update on Regeneron's performance for the quarter ending March 31, 2014.
- 4Investors are directed to the furnished press release for comprehensive information.
- 5Information furnished under Item 2.02 is not deemed 'filed' for certain regulatory purposes but is crucial for investor understanding of current performance.
Frequently Asked Questions
This 8-K filing primarily serves to announce and provide access to Regeneron Pharmaceuticals' financial and operating results for the first quarter of 2014, which ended on March 31, 2014.
The detailed Q1 2014 financial and operating results are contained within the press release dated May 8, 2014, which is filed as Exhibit 99.1 to this 8-K and incorporated by reference.
The information provided under Item 2.02 and the attached press release are considered 'furnished,' meaning they are not subject to the liabilities of Section 18 of the Securities Exchange Act of 1934 in the same way as 'filed' information. However, for investors, this furnished information is critical for understanding the company's current financial and operational performance.